Introducing Accel Apollo! It brings current software, a more capable statistical computing environment architecture, and better tools for R and Python to the biostatistics teams that run clinical analysis every day.
In this blog, we discuss the hidden cost of PC-SAS, fragmentation, and manual validation.
In this blog, we discuss PPD, what different agencies actually care about, and how to navigate CTT language in an ever-changing regulatory landscape.
With the release of Blur™ 2.10, Instem is introducing a broad set of enhancements across CSR anonymization, data de-identification, risk simulation, administration, performance, and security.
This blog examines how clinical trial transparency regulations are evolving and what organizations can do to keep up with expectations.
BOSTON, USA – 21 April 2026: d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades...
